VC-Backed Bust: Dynogen Pharma

Dynogen Pharmaceuticals Inc., a Waltham, Mass.-based drug company focused on gastrointestinal and genitourinary disorders, has filed to liquidate under Chapter 7 bankruptcy protection. It listed liabilities of $10.6 million, and assets of less than 20,000. The company last year scrapped plans to go public via a reverse merger with a SPAC called Apex Bioventures Acquisition Corp., and said it would seek out new funding. As of that time, Dynogen had raised around $67 million from firms like Atlas Venture, HealthCare Ventures, Oxford Bioscience Partners, Abingworth Management, Medica Venture Partners and Pappas Ventures. www.dynogen.com

Leave a Reply

PEHUB Community

Join the 12504 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget